Liver Cancer
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 1, 2004; 10(11): 1560-1564
Published online Jun 1, 2004. doi: 10.3748/wjg.v10.i11.1560
Quantitative detection of common deletion of mitochondrial DNA in hepatocellular carcinoma and hepatocellular nodular hyperplasia
Jian-Yong Shao, Hong-Yi Gao, Yu-Hong Li, Yu Zhang, You-Yong Lu, Yi-Xin Zeng
Jian-Yong Shao, Hong-Yi Gao, Yu-Hong Li, Yu Zhang, Yi-Xin Zeng, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, Guangdong Province, China
You-Yong Lu, Beijing Institute for Cancer Research, Beijing Laboratory of Molecular Oncology, School of Oncology, Peking University, Beijing 100034, China
Author contributions: All authors contributed equally to the work.
Supported by the National Key Basic Science Research Program, Contract No: G1998051201; The Foundation of Guangdong Science and Technology Committee, Contract No: 2003A3080202; and The Foundation of Guangzhou Science and Technology Committee, Contract No: 2003I-E0341
Correspondence to: Jian-Yong Shao, M.D., Ph.D., Department of Pathology, Cancer Center, Sun Yat-Sen University, 651 Dong Feng Road East, Guangzhou 510060, Guangdong Province, China. jyshao@gzsums.edu.cn
Telephone: +86-20-87343391 Fax: +86-20-87343391
Received: August 23, 2003
Revised: October 4, 2003
Accepted: October 12, 2003
Published online: June 1, 2004

Abstract

AIM: To study the deletion of mitochondiral DNA in hepatocellular carcinoma and hepatocellular nodular hyperplasia and its significance in the development of cancer.

METHODS: Deleted mtDNA (CD-mtDNA) and wild type mtDNA (WT-mtDNA) were quantitatively analyzed by using real-time PCR in 27 hepatocellular carcinomas (HCC) and corresponding noncancerous liver tissues and 27 hepatocellular nodular hyperplasiae (HNH).

RESULTS: A novel CD (4981 bp) was detected in 85% (23/27) and 83% (22/27) of HCC and HNH tumor tissues, respectively, which were significantly higher than that in paired noncancerous liver tissues (57%, 15/27) (P < 0.05). The CD/WT-mtDNA ratio in HCC tumors was 0.00092 (median, interquartile range, 0.0001202 - 0.00105), which was significantly higher than that in paired noncancerous liver tissues (median, 0.000, quartile range, 0 - 0) (P = 0.002, Mann-Whitney Test), and was 25 of times of that in HNH tissues (median, 0.0000374, quartile range, 0 - 0.0004225) (P = 0.002, Mann-Whitney test).

CONCLUSION: CD-mtDNA mutation plays an important role in the development and progression of HCC.




INTRODUCTION

Heptacellular carcinoma (HCC) is one of the common malignancies worldwide, and has been ranked the 2nd cancer killer in China. Hepatitis B and C viruses (HBV and HCV) and dietary aflatoxin intake remain the major causative factors of HCC[1]. Previous studies also revealed that frequent genetic aberrations were involved in heptocarcinogenesis[2,3]. However, the molecular mechanisms of hepatocarcinogenesis remain unclear. Recently, morphological features of the tumor, both gross and histological, have been found to be significantly associated with tumor recurrence and patient survival.

Nuclear gene alterations are correlated to invasion, metastasis, recurrence of HCC,which are regarded as biomarkers for the malignant phenotype of HCC, and related to the prognosis and therapeutic outcomes. These biomarkers include p53 gene mutation[4], VEGF overexpression[5,6], apoptosis related genes, cell adhesion and extracellular matrix related genes such as E-cadherin, b-catenins, CD44s, MMPs and their inhibitor TIMPs[7-13].

Human mitochaondrial DNA (mtDNA) is located in cytoplasm, is becoming the study hotspot for its alteration in correlation with its tumorigenesis. Mitochondria are involved in apoptosis[14], and probably also tumorigenesis[15], which has led researchers to examination the potential roles of mtDNA alterations in the development and maintenance of cancers.

The most abundant change in mtDNA is called common deletion (4977 bp, CD). CD-containing mitochondrial DNA (CD-mtDNA) was first observed in patients with mitochondrial myopathies, and was also found to accumulate in patients with heteroplasmic mtDNA mutations and in normal individuals during aging, particularly in postmitotic tissues such as muscle and brain[16]. The CD-mtDNA mutation has been detected in several types of human tumors including thyroid Hürthle cell tumor[17], gastric cancer[18], and hepatocellular carcinoma[19]. However, knowledge about the common deletion of mtDNA in HCC in China is poor. This is the first report of a high incidence (70%) of a novel CD-mtDNA (4981 bp) in tumor tissues of HCC and hepatocellular nodular hyperplasia (HNH) from southern China, and the first analysis correlating CD-mtDNA level to clinicopathological parameters and age.

MATERIALS AND METHODS
Clinical data and histopathologic analysis of tumor samples

Patients with histologically proved HCC and HNH at the Cancer Center, Sun Yat-Sen University (Guangzhou, China) were recruited with informed consent from January 1999 to January 2003. Samples consisted of 27 surgically resected HCC and 27 HNH specimens. In HCC specimens, the tumor tissue and paired adjacent noncancerous liver tissue were obtained independently for mtDNA analysis. In serum, hepatitis B viral surface antigen and HCV antibody titer were detected by enzymed-linked immunosorbent assay and radio-immunoassay. Grading of differentiation was performed according to the method of Edmondson and Steiner. Tumors were classified into well differentiated group (grades 1 and 2) and poorly differentiated group (grades 3 and 4). The tumor size was classified into small (tumor mass < 3 cm in greatest diameter) and large (tumor mass size > 3 cm in greatest diameter). There were 24 males and 3 females aged from 40 to 79 years, with an average age of 58 years.

DNA extraction

Total (nuclear and mitochondria) DNA was extracted from paraffin-embedded tissues of HNH, HCC and adjacent noncancerous liver tissues using the QIAamp DNeasy Tissue Kit (Qiagen, Hilden, Germany). Prior to DNA extraction, a microdissection technique was used in certain cases when tumor tissues and non-tumor tissues were mixed in one sample to enrich tumor cells[20]. Five 10- μm thick sections were cut and placed into a 1.5 mL Eppendorff tube. The sections were deparaffinized twice with xylene and alcohol.

Conventional PCR detection of CD-mtDNA

In this investigation, we developed a real-time PCR protocol that reliably quantified mtDNA through amplification of different regions of the mitochondrial genomes: one just outside the CD region in cytochrome c oxidase II (MTCO2) coding region (IS), and one overlapping the CD itself (Figure 1). PCR primers for detection of CD-mtDNA were designed according to MITOMAP Human mtDNA Cambridge Sequence data (http://www. mitomap.org). Real-time PCR primers and fluorogenic probes for regions of WT-mtDNA (forward primer, L7878-7897; reverse primer, H7979-7958; probe, L7899-7917) and CD-mtDNA (forward primer, L8448-8472; reverse primer, H13560-13539; probe, L13456-13471) were designed with the Primer Express software (Table 1).

Figure 1
Figure 1 Human mitochondrial DNA showing the 4997-bp deletion. The genes disrupted by the 4997 bp deletion between nucleotide positions 8469 and 13447 encode four polypeptides for complex I (ND3, ND4, ND4L and ND5), one for complex IV (CO III) and two for complex V (ATP8 and ATP6), and five tRNA genes for the amino acids G, R, H, S and L. CD represent the PCR primers position that flank the common deletion region.

Conventional PCR was performed in 20 μL volume consisting of 2 μL 10 × PCR buffer, 25 μmol/L of each dNTP, 2.5 U Taq polymerase, 15 pmol/L of each primer and 50 ng of DNA template. The reaction was performed in a PE2700 thermocycler (Applied Biosystem Inc., USA). PCR reaction included at 95 °C for 10 min, 40 cycles at 94 °C for 30 s, at 60 °C for 30 s and at 72 °C for 30 s. The PCR products were separated on 20 g/L agarose gels at 80 V for 60 min, visualized by ethidium bromide staining and UV light, and photographed. The results of amplification of CD-mtDNA by conventional PCR in HCC and HNH tissues are shown in Figure 2A

Figure 2
Figure 2 Detection results of CD-mtDNA in HCC. A: Conven-tional PCR results: Lane M, marker, Lane 1, negative control, Lane 2, positive control, Lane 3-4, nasopharygitis samples, and Lane 5-8, NPC samples; B: Real-time PCR result shows the amplification plot of fluorescence intensity against the PCR cycle. Each plot corresponds to a HCC sample. The X axis denotes the cycle number of a quantitative PCR reaction. The Y axis denotes the Rn, which is the fluorescence intensity over the background. The correlation coefficient is 0.994.
Table 1 TaqMan primers and probes for detection of WT-mtDNA and CD-mtDNA.
TargetAmpliconOligonucleotide sequence (5’-3’)
Wild Type mtDNA101 bpWT1 forward primer (7878-7897) : 5´-AATCAATTGGCGACCAATGG-3´
WT2 reverse primer (7979-7958) : 5´-CGCCTGGTTCTAGGAATAATGG-3´
WT probe (7899-7917) : 5’FAM-ACTGAACCTACGAGTACAC-MGB-3’
Common Deletion mtDNA132 bpCD1 forward primer (8448-8472) : 5’-TATTAAACACAAACTACCACCTACC-3’
CD2 reverse primer (13560-13539) : 5’-GGCTCAGGCGTTTGTGTATGAT-3’
CD probe: (13456-13471) : 5’FAM- ACC ATTGGC AGC CTA G -MGB 3’
TaqMan-PCR

The principles of real-time PCR and methods for absolutely quantification of target DNA were described[18]. The quantitative TaqMan-PCR method could provide real-time measurement of target input.

Triplicate amplification reactions were performed in a 96-well microplate. Total WT-mtDNA and CD-mtDNA reactions (25 μL) each containing 100 ng DNA, 1 × TaqMan Universal PCR Master Mix, 300 mmol/L of each dNTP and 300 mmol/Lof each IS or CD primer were performed. The reactions were completed by adding 100 nmol/L of the specific WT or CD probe. PCR and fluorescence analysis were performed using the ABI GeneAmp 7900HT sequence detection system (Applied Biosystems Inc., USA). Amplification conditions included at 50 °C for 2 min (for optimal AmpErase UNG activity), at 95 °C for 10 min (for deactivation of AmpErase UNG and activation of AmpliTaq Gold), then 40 cycles at 95 °C 15 s and at 60 °C for 1 min (for probe/primer hybridization and DNA synthesis).

Analysis of the reactions was carried out in an ABI PRISM 7900HT sequence detector equipped with the sequence detection software version 2.0 (PE Applied Biosystems, Foster City, USA). Absolute DNA quantification was performed using the standard curve method. Reactions were carried out with different concentrations (1010, 109, 108, 107, 106, 105, 104 copies/mL) of two standard plasmids in parallel with test reactions. The standard plasmids, one carrying sequences flanking the common deletion and one carrying a unique mtDNA sequence independent of the CD, allowed the generation of two standard curves showing the number of copies of total WT-mtDNA or CD-mtDNA versus the measured CT. The CT values of samples were then converted to the number of DNA copies by comparing the sample CT to that of a known concentration of plasmid DNA. The amount of mutation corresponded to the concentration ratio of CD-mtDNA to WT-mtDNA within each sample. If DNA was not detected within 40 cycles (CT = 40), it was considered absent from a particular sample. The amplification plot CD-mtDNA detected by TaqMan PCR in HCC tissues is presented in Figure 2B.

The CD-mtDNA PCR products were sequenced using the ABI PRISM BigDye termination cycle sequencing ready reaction kit on an ABI PRISM377 sequencer (Applied Biosystem Inc., USA). Blast sequencing analysis confirmed that PCR products of the CD-mtDNA were homologous to the Cambridge version of the mtDNA sequence.

Statistical analysis

The levels of CD/MT-mtDNA ratio in different groups were compared using the Mann-Whitney rank-sum test. The chi-square test and Fisher’s exact test were used to assess the difference in different groups. A P value less than 0.05 was considered statistically significant.

RESULTS

The 132 bp PCR fragment amplified from CD-mtDNA was cloned and sequenced to confirm the deletion junction created by the CD, which was characterized by the presence of one of the two 13 bp repeats that normally flanked wild-type mtDNA. Sequence comparison (Human mtDNA Cambridge Sequence data, http://www. mitomap.org) revealed that the common deletion region in our HCC samples was a 4981 bp fragment extending from position 8470 bp to 13450 bp (Figure 3). This was a novel mtDNA deletion belonging to the 4977 bp deletion subtype that was first reported in liver diseases.

Figure 3
Figure 3 Sequencing result of the amplified CD-mtDNA from HCC. Comparison with the MITOMAP Human mtDNA Cambridge Sequence data (http://www.mitomap.org), the deletion region (red bar region) is a 4981 bp deletion from position 8470 to 13450 of the mtDNA.
Incidence of CD-mtDNA by conventional PCR detection

CD-mtDNA was detected by conventional PCR in 70% (19/27), 63% (17/27) and 44% (12/27) in HCC tumors, HNH tissues and HCC adjacent liver tissues, respectively. The detected rate of CD-mtDNA in HCC and HNH tumors by conventional PCR was significantly higher than that in adjacent liver tissues (P < 0.05, chi-square test). There was no significant difference in CD-mtDNA detected rate between HCC and HNH (P > 0.05, chi-square test).

By quantitative TaqMan-PCR, the detection rate of CD-mtDNA in HCC tumors, HNH tissues and adjacent liver tissues was 70% (19/27), 63% (17/27) and 44% (12/27), respectively. When these results were combined with those of conventional PCR, CD-mtDNA was detected in 85% (23/27) of HCC, 83% (22/27) of HNH, and 57% (15/27) of HCC paired adjacent liver tissues. The detected CD-mtDNA rate in HCC and HNH tumors was significantly higher than that in paired noncancerous liver tissues (P < 0.05, chi-square test). (Figure 4).

Figure 4
Figure 4 Correlations of CD-mtDNA with HCC and HNH. The CD-mtDNA rate in HCC and HNH lesions was signifi-cantly higher than that in paired noncancerous tissues; the CD/WT-mtDNA ratio in HCC was significant higher than that in paired noncancerous liver tissues (P = 0.02), and was about 25 times that in HNH lesions (P = 0.02).
CD/WT-mtDNA ratio in HCC and HNH lesions

We evaluated the relative level of CD-mtDNA by calculating the ratio of CD-mtDNA to WT-mtDNA in each sample. In this study, the CD/WT-mtDNA ratio was 0.00092 (median, interquartile range, 0.0001202 - 0.00105) in HCC tumor, 0.000 (median, quartile range, 0 - 0) in paired noncancerous liver tissues, and 0.0000374 (median, quartile range, 0 - 0.0004225) in HNH tissues. The CD/WT -mtDNA ratio in HCC tumor was significantly higher than that in paired noncancerous liver tissues (P = 0.002, Mann-Whitney test), and was 25 times of that in HNH tissues (P = 0.002, Mann-Whitney test, Figure 4). No correlation of the detected rate and the ratio of CD-mtDNA with ageing, staging, tumor size, HBV infection and differentiation of patients with HCC were found.

DISCUSSION

It has been found that human mitochondrial DNA (mtDNA) has a double-stranded circular molecule of 16569 bp that encodes 37 genes: 2 rRNAs, 22 tRNAs and 13 polypeptides[21]. The mtDNA was present in high copy levels (103 - 104 copies per cell) in virtually all cells, and the vast majority of an individual’s copies were identical at birth[22]. It has been generally accepted that high mutation rates of mtDNA are caused by a lack of protective histones, inefficient DNA repair systems, and continuous exposure to mutagenic effects of oxygen radicals generated by oxidative phosphorylation[23,24]. The deletion was thought to be the product of an intragenomic recombination event between two 13 bp direct repeats (positions 8470 - 8482 and 13447 - 13459) after a single-strand break caused by ultraviolet A (UVA) or ROS[25].

Recently, somatic mutations in mitochondrial DNA (mtDNA) have been detected in various cancers including HCC. Mutations in the D-loop were frequent events and could be used as a molecular tool to determine clonality of HCC[26]. There are controversial reports of CD-mtDNA mutation in HCC. CD-mtDNA was reported to be detected in HCC tumors and noncancerous liver tissues, whereas lower level even no CD-mtDNA was detected in HCC tumors[27,28]. In this investigation, we detected a novel CD-mtDNA mutation (4981 bp) in 85% HCC, which was higher than that in gastric cancer (50%)[18], but less than that in thyroid Hürthle cell tumors (100%)[17]. Moreover, we found that both the detected CD-mtDNA rate and CD/WT-mtDNA ratio in HCC were higher than those in paired noncancerous liver tissues of individuals with HCC. This result was different from previous studies. The different risk factors and different genetic background in HCC tumorigenesis between Chinese and Japanese might explain the disparity of the results. Further studies are required to determine if CD-mtDNA mutation is correlated with malignant transformation.

However, the biological impact of mtDNA deletion on HCC tumors is not entirely clear. Defects in mitochondrial function have long been suspected to contribute to the development and progression of cancer. These mutations could contribute to neoplastic transformation by changing cellular energy capacities, increasing mitochondrial oxidative stress, and/or modulating apoptosis[25]. Diaz et al[29] reported that mtDNA with large deletions, but not with pathogenic point mutations, repopulated organelles significantly faster than wild-type genomes in the same cell. Under proliferating conditions, cells harboring relatively high levels of deleted mtDNAs showed a slight reduction in the mutated fraction. This was consistent with the observation that patients with mitochondrial diseases had relatively low percentages of mutated mtDNA in proliferating peripheral blood cells and fibroblasts[30]. This situation paralleled the accumulation of large-scale mtDNA deletions in postmitotic tissues, where selection based on cellular growth or survival did not take place, and abnormal organelle proliferation would lead to an increase in mtDNA replication rates[31,32]. Amuthanl[33] showed that damage to mtDNA and the mitochondrial membrane might change nuclear gene expression, leading to overexpression of genes including cathepsin L, transforming growth factor (TGFb), and mouse melanoma antigen (MMA), which are well known markers for tumor progression. Singh[34] showed that mtDNA played an important role in cellular sensitivity to cancer therapeutic agents. Since each cell contains many mitochondria with multiple copies of mtDNAs, it is possible that wild-type and mutant mtDNA can co-exist in a state called heteroplasmy. Thus, the biological impact of a given mutation may vary, depending on the proportion of mutant mtDNAs carried by individuals.

It has been shown that mtDNA deletions accumulate with age in many tissues. However, in tumors, the CD has been associated with external factors such as radiation and cigarette smoking[35-37]. In this investigation, we found that although there was no significant difference in detected CD-mtDNA rate between HCC and paired adjacent liver tissues as well as HNH, the CD-mtDNA ratio in HCC was significantly higher than that in HNH (25-fold) and paired noncancerous liver tissues. These results suggest that CD-mtDNA mutation may be accumulated during the hepatocyte transformation. No correlation of CD-mtDNA with ageing, staging and HBV infection of the individuals with HCC and HNH was found. In this investigation, the high detected rate and high ratio of CD-mtDNA in HCC and HNH suggested that this rapid and quantitative assay of CD-mtDNA and WT-mtDNA copy number was potentially useful in a variety of molecular and evolutionary fields of HCC.

In conclusion, this is the first quantitative study of frequent occurrence of CD-mtDNA mutations in patients with HCC. This study provides further evidence that CD-mtDNA mutation might play an important role in the development and progression of HCC. Studies evaluating the CD-mtDNA mutations as a biomarker may be potentially useful for early diagnosis of HCC.

Footnotes

Edited by Ren SY and Wang XL Proofread by Xu FM

References
1.  Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2001;7:445-454.  [PubMed]  [DOI]
2.  Shao J, Li Y, Li H, Wu Q, Hou J, Liew C. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas. Chin Med J (Engl). 2000;113:817-822.  [PubMed]  [DOI]
3.  Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res. 1994;54:281-285.  [PubMed]  [DOI]
4.  Shiota G, Kishimoto Y, Suyama A, Okubo M, Katayama S, Harada K, Ishida M, Hori K, Suou T, Kawasaki H. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J Hepatol. 1997;27:661-668.  [PubMed]  [DOI]
5.  Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001;233:227-235.  [PubMed]  [DOI]
6.  Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LH. Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol. 2000;6:565-568.  [PubMed]  [DOI]
7.  Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology. 2002;36:692-701.  [PubMed]  [DOI]
8.  Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol. 2000;31:558-565.  [PubMed]  [DOI]
9.  Cui J, Zhou XD, Liu YK, Tang ZY, Zile MH. Abnormal beta-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China. World J Gastroenterol. 2001;7:542-546.  [PubMed]  [DOI]
10.  Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 2000;32:78-84.  [PubMed]  [DOI]
11.  Jiang YF, Yang ZH, Hu JQ. Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol. 2000;6:61-65.  [PubMed]  [DOI]
12.  Bu W, Huang X, Tang Z. [The role of MMP-2 in the invasion and metastasis of hepatocellular carcinoma (HCC)]. Zhonghua Yixue Zazhi. 1997;77:661-664.  [PubMed]  [DOI]
13.  Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol. 2001;195:236-243.  [PubMed]  [DOI]
14.  Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.  [PubMed]  [DOI]
15.  Cavalli LR, Liang BC. Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved. Mutat Res. 1998;398:19-26.  [PubMed]  [DOI]
16.  Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet. 1992;2:324-329.  [PubMed]  [DOI]
17.  Máximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simões M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol. 2002;160:1857-1865.  [PubMed]  [DOI]
18.  Máximo V, Soares P, Seruca R, Rocha AS, Castro P, Sobrinho-Simões M. Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. Genes Chromosomes Cancer. 2001;32:136-143.  [PubMed]  [DOI]
19.  Fukushima S, Honda K, Awane M, Yamamoto E, Takeda R, Kaneko I, Tanaka A, Morimoto T, Tanaka K, Yamaoka Y. The frequency of 4977 base pair deletion of mitochondrial DNA in various types of liver disease and in normal liver. Hepatology. 1995;21:1547-1551.  [PubMed]  [DOI]
20.  Moskaluk CA, Kern SE. Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol. 1997;150:1547-1552.  [PubMed]  [DOI]
21.  Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F. Sequence and organization of the human mitochondrial genome. Nature. 1981;290:457-465.  [PubMed]  [DOI]
22.  Lightowlers RN, Chinnery PF, Turnbull DM, Howell N. Mammalian mitochondrial genetics: heredity, heteroplasmy and disease. Trends Genet. 1997;13:450-455.  [PubMed]  [DOI]
23.  Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem. 1992;61:1175-1212.  [PubMed]  [DOI]
24.  Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases. Science. 1992;256:628-632.  [PubMed]  [DOI]
25.  Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. Proc Natl Acad Sci USA. 1989;86:7952-7956.  [PubMed]  [DOI]
26.  Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res. 2002;8:481-487.  [PubMed]  [DOI]
27.  Nishikawa M, Nishiguchi S, Shiomi S, Tamori A, Koh N, Takeda T, Kubo S, Hirohashi K, Kinoshita H, Sato E. Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res. 2001;61:1843-1845.  [PubMed]  [DOI]
28.  Yamamoto H, Tanaka M, Katayama M, Obayashi T, Nimura Y, Ozawa T. Significant existence of deleted mitochondrial DNA in cirrhotic liver surrounding hepatic tumor. Biochem Biophys Res Commun. 1992;182:913-920.  [PubMed]  [DOI]
29.  Diaz F, Bayona-Bafaluy MP, Rana M, Mora M, Hao H, Moraes CT. Human mitochondrial DNA with large deletions repopulates organelles faster than full-length genomes under relaxed copy number control. Nucleic Acids Res. 2002;30:4626-4633.  [PubMed]  [DOI]
30.  Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, Nakase H, Bonilla E, Werneck LC, Servidei S. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med. 1989;320:1293-1299.  [PubMed]  [DOI]
31.  Johnston W, Karpati G, Carpenter S, Arnold D, Shoubridge EA. Late-onset mitochondrial myopathy. Ann Neurol. 1995;37:16-23.  [PubMed]  [DOI]
32.  Moslemi AR, Melberg A, Holme E, Oldfors A. Clonal expansion of mitochondrial DNA with multiple deletions in autosomal dominant progressive external ophthalmoplegia. Ann Neurol. 1996;40:707-713.  [PubMed]  [DOI]
33.  Amuthan G, Biswas G, Zhang SY, Klein-Szanto A, Vijayasarathy C, Avadhani NG. Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J. 2001;20:1910-1920.  [PubMed]  [DOI]
34.  Singh KK, Russell J, Sigala B, Zhang Y, Williams J, Keshav KF. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene. 1999;18:6641-6646.  [PubMed]  [DOI]
35.  Kotake K, Nonami T, Kurokawa T, Nakao A, Murakami T, Shimomura Y. Human livers with cirrhosis and hepatocellular carcinoma have less mitochondrial DNA deletion than normal human livers. Life Sci. 1999;64:1785-1791.  [PubMed]  [DOI]
36.  Rogounovitch TI, Saenko VA, Shimizu-Yoshida Y, Abrosimov AY, Lushnikov EF, Roumiantsev PO, Ohtsuru A, Namba H, Tsyb AF, Yamashita S. Large deletions in mitochondrial DNA in radiation-associated human thyroid tumors. Cancer Res. 2002;62:7031-7041.  [PubMed]  [DOI]
37.  Ballinger SW, Bouder TG, Davis GS, Judice SA, Nicklas JA, Albertini RJ. Mitochondrial genome damage associated with cigarette smoking. Cancer Res. 1996;56:5692-5697.  [PubMed]  [DOI]